Aurora Cannabis Partners with Vectura Fertin Pharma

Ticker: ACB · Form: 6-K · Filed: 2024-08-06T00:00:00.000Z

Sentiment: neutral

Topics: collaboration, medical-cannabis, pharmaceuticals

TL;DR

Aurora Cannabis teams up with Vectura Fertin Pharma for new medical cannabis products.

AI Summary

Aurora Cannabis Inc. announced a commercial collaboration with Vectura Fertin Pharma, Inc. on August 1, 2024. This partnership aims to leverage Vectura Fertin Pharma's expertise in inhalation technology and Aurora's global medical cannabis portfolio to develop and commercialize new medical cannabis products.

Why It Matters

This collaboration could lead to innovative medical cannabis products for patients, potentially expanding Aurora's market reach and product offerings in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — The success of this collaboration depends on product development, regulatory approvals, and market adoption, introducing inherent risks.

Key Players & Entities

FAQ

What is the primary goal of the commercial collaboration between Aurora Cannabis and Vectura Fertin Pharma?

The primary goal is to leverage Vectura Fertin Pharma's inhalation technology and Aurora's medical cannabis portfolio to develop and commercialize new medical cannabis products.

When was the news release announcing this collaboration issued?

The news release was issued on August 1, 2024.

Which company is responsible for the inhalation technology expertise in this partnership?

Vectura Fertin Pharma, Inc. is responsible for the inhalation technology expertise.

What type of products are expected to be developed from this collaboration?

New medical cannabis products are expected to be developed.

Who signed the Form 6-K report on behalf of Aurora Cannabis Inc.?

Miguel Martin, Chief Executive Officer, signed the Form 6-K report.

From the Filing

0001279569-24-000965.txt : 20240806 0001279569-24-000965.hdr.sgml : 20240806 20240805175752 ACCESSION NUMBER: 0001279569-24-000965 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20240801 FILED AS OF DATE: 20240806 DATE AS OF CHANGE: 20240805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AURORA CANNABIS INC CENTRAL INDEX KEY: 0001683541 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38691 FILM NUMBER: 241176341 BUSINESS ADDRESS: STREET 1: 2207 90B STREET SW CITY: EDMONTON STATE: A0 ZIP: T6X 1V8 BUSINESS PHONE: 604-362-5207 MAIL ADDRESS: STREET 1: 409 GRANVILLE STREET STREET 2: SUITE 1700 CITY: VANCOUVER STATE: A1 ZIP: V6C 1T2 6-K 1 aurora_6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File No. 001-38691 AURORA CANNABIS INC. (Translation of registrant's name into English) 2207 90B St. SW Edmonton, Alberta T6X 1V8 Canada (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☐ Form 40-F ☒ SUBMITTED HEREWITH Exhibits Description 99.1 News Release dated August 1, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. AURORA CANNABIS INC. /s/ Miguel Martin Miguel Martin Chief Executive Officer Date: August 1, 2024 EX-99.1 2 ex991.htm NEWS RELEASE DATED AUGUST 1, 2024 Exhibit 99.1 Aurora Cannabis and Vectura Fertin Pharma, Inc. announce commercial collaboration Collaboration will initially see launch of a new CBD lozenge from Cogent International, a Vectura Fertin Pharma subsidiary, on Aurora's Canadian medical cannabis patient platform Following successful launch of CBD lozenge, the collaboration will explore the potential to launch Vectura Fertin Pharma's future medical cannabis portfolio in Canada EDMONTON, AB, and STAMFORD, Conn., Aug. 1, 2024 /CNW/ - Aurora Cannabis Inc. (" Aurora ") (NASDAQ: ACB) (TSX: ACB), a leading Canadian-based global medical cannabis company, and Vectura Fertin Pharma, Inc., an innovator in wellness and healthcare, are pleased to announce that Aurora has entered into a commercial collaboration with Cogent International Manufacturing Ltd. (" Cogent "), a wholly-owned subsidiary of Vectura Fertin Pharma Inc. Through this arrangement, Cogent will initially launch its newly developed CBD lozenge on Aurora's Canadian medical cannabis patient platform, giving access to patient feedback which will be used to validate the product proposition and patient responses to the product while building real-world patient data for future analysis. Following the successful launch of the CBD lozenge, the two companies may explore opportunities regarding the potential commercialization of other Vectura Fertin Pharma medical cannabis products in Canada. "We are excited about this commercial collaboration that will allow Aurora to leverage its industry-leading patient platform in Canada to support advancements in medical cannabis, as well as to provide our patients with access to Vectura Fertin Pharma's new CBD lozenge," said Miguel Martin, CEO for Aurora. "As a global leader in the manufacturing of pharmaceutical-grade medical cannabis, we are pleased to see increased interest in the possibilities of medical cannabis as part of healthcare options made available to Canadians." Michael Kunst, CEO for Vectura Fertin Pharma, said: "At Vectura Fertin Pharma, we are committed to build

View on Read The Filing